MDM2:瘤治疗的研究现状和前景
Yumei Yao1, Qian Zhang1, Zhi Li1
1Zhaotong Health Vocational College, No 603 Yucai Road, Zhaotong City, Yunnan Province, 657000, People's Republic of China.
Cancer cell international
|May 13, 2024
概括
针对小鼠双分钟2 (MDM2) 提供了一个有希望的策略,以重新激活癌症中的p53瘤抑制活性. MDM2 抑制剂还显示出提高癌症免疫治疗有效性的潜力.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药物发现 药物发现 药物发现
背景情况:
- 鼠标双分钟2 (MDM2) 通过ubiquitination和降解负面调节p53瘤抑制蛋白.
- 在人类癌症中,p53的失活是常见的,这使得直接的p53向难以实现.
- 针对p53-MDM2相互作用是癌症治疗的关键策略.
研究的目的:
- 审查MDM2.2的分子特性.
- 要总结当前关于MDM2向抑制剂的研究.
- 探索MDM2向对免疫治疗疗效的影响.
主要方法:
- 关于MDM2功能和抑制剂的文献综述.
- 对p53-MDM2相互作用调制研究的分析.
- 检查MDM2表达和免疫治疗反应之间的相关性.
主要成果:
- 已经确定了各种抑制MDM2或p53酸化的化合物.
- MDM2表达与免疫疗法的有效性相关,特别是在免疫检查点抑制中.
- 向MDM2可能会恢复p53功能并增强抗癌免疫力.
结论:
- MDM2 抑制剂对具有p53通路改变的癌症是一种可行的治疗方法.
- 调节p53-MDM2轴可能会改善癌症免疫治疗的结果.
- 为了开发针对MDM2的药物和优化组合疗法,需要进一步的研究.
更多相关视频
09:33Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
Published on: August 25, 2023
1.1K
13:41Magnetic Resonance-Guided High Intensity Focused Ultrasound Generated Hyperthermia: A Feasible Treatment Method in a Murine Rhabdomyosarcoma Model
Published on: January 13, 2023
2.3K
相关概念视频
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Mitogens and the Cell Cycle
6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Tumor Progression
6.3K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.3K
M-Cdk Drives Transition Into Mitosis
5.6K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.6K
